Abstracts tagged "Biologic agents and psoriatic arthritis"

Abstract Number: 2555 • 2018 ACR/ARHP Annual Meeting
Ixekizumab Treatment Results in Rapid and Sustained Improvements in the Disease Activity Index for Psoriatic Arthritis (DAPSA) in Patients Naïve to Biologic Dmards or with Previous Inadequate Response to TNF Inhibitors
Prashanth Sunkureddi¹, Baojin Zhu^2,3, Alexis Ogdie⁴, Aubrey Spraberry³, Jeffrey Lisse³, Chen-Yen Lin³ and David Shrom², ¹Rheumatology, Clear Lake Rheumatology Center, Nassau Bay, TX, ²LRL, Eli Lilly and Company, Indianapolis, IN, ³Eli Lilly and Company, Indianapolis, IN, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: The DAPSA is a composite tool that assesses several domains of psoriatic arthritis (PsA) manifestations and was developed as a disease activity measure for…
Abstract Number: 2602 • 2018 ACR/ARHP Annual Meeting
Evolution of Patient Characteristics in the Era of Biological Treatment of Psoriatic Arthritis: 18-Year Belgian Experience from Leuven Spondyloarthritis Biologics Cohort (BioSPAR)
Alla Ishchenko¹, Rik Lories² and Kurt de Vlam³, ¹Rheumatology, KU Leuven, Skeletal Biology and Engineering Research Center & University Hospitals Leuven, Leuven, Belgium, ²Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium, ³UZ Leuven, Leuven, Belgium
Background/Purpose: Biologicals revolutionized the management of PsA. Since the introduction of the first TNF inhibitor (TNFi) in the early 2000s, therapeutic options for PsA are…
Abstract Number: 1564 • 2017 ACR/ARHP Annual Meeting
Treatment Patterns, Survival and Long-Term Effectiveness of Biological Agents in Psoriatic Arthritis Patients
Marina Natalia Fornaro¹, Fernando Dal Pra², Emilce E Schneeberger², Osvaldo Luis Cerda², Margarita Landi², María de los Angeles Correa³, Rodrigo Garcia Salinas⁴, Sebastian Magri⁵, Raul Sueldo⁶, María Julia Santa Cruz⁷, Emilio Buschiazzo⁸ and Gustavo Citera⁹, ¹Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, buenos aires, Argentina, ²Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ³Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Buenos Aires, Argentina, ⁴Section of Rheumatology, Hospital Italiano de La Plata, Buenos Aires, Argentina, La Plata, Argentina, ⁵Section of Rheumatology, Hospital Italiano de La Plata, La Plata, Argentina, ⁶Section of Rheumatology, Hospital Angel Cruz Padilla, Tucumán, Argentina, ⁷Section of Rheumatology, Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ⁸Section of Rheumatology, Hospital Señor del Milagro, Salta, Argentina, Salta, Argentina, ⁹Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina
Background/Purpose: The incorporation of biological disease modifying drugs (b-DMARD) has substantially improved the outcome of patients with Psoriatic Arthritis (PsA). Our aim was to evaluate…
Abstract Number: 4L • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety Results of Guselkumab, an Anti-IL23 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis over 24 Weeks: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study
Atul A. Deodhar¹, Alice B Gottlieb², Wolf-Henning Boehncke³, Bin Dong⁴, Yuhua Wang⁴, William Barchuk⁵, Xie Xu⁵ and Elizabeth C. Hsia⁴, ¹Oregon Health & Science University, Portland, OR, ²Department of Dermatology, New York Medical College, Valhalla, NY, ³Department of Dermatology,, Geneva University Hospital, Geneva, Switzerland, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC, San Diego, CA
Background/Purpose: To evaluate the efficacy, safety, and tolerability of guselkumab (GUS), a fully human monoclonal antibody against the p19 subunit of IL-23, in patients (pts)…
Abstract Number: 1554 • 2014 ACR/ARHP Annual Meeting
Early and Sustained Modified Psarc Response in Psoriatic Arthritis Patients Treated with Ustekinumab: Results from 2 Phase 3 Studies
Iain B. McInnes¹, Christopher T. Ritchlin², Proton Rahman³, Lluís Puig Sanz⁴, Alice B. Gottlieb⁵, Shu Li⁶, Michael Song⁶, Bruce Randazzo⁶, Yuhua Wang⁶, Alan M. Mendelsohn⁷ and Arthur Kavanaugh⁸, ¹University of Glasgow, Glasgow, United Kingdom, ²Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ³Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁴Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁵Tufts Medical Center, Boston, MA, ⁶Janssen Research & Development, LLC., Spring House, PA, ⁷Immunology, Janssen Research & Development, LLC., Spring House, PA, ⁸University of California San Diego, La Jolla, CA
Background/Purpose: We have previously reported the efficacy and safety results of ustekinumab (UST), an IL-12/23 p40 inhibitor, in patients with active psoriatic arthritis (PsA) up…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].